Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MicroPort CardioFlow MedtechMROPF 59 Debt-to-Equity is 0.91 as of Dec. 2025, which is 2175% above its 10-year median of 0.04. GuruFocus rates MROPF with a GF Score™ of 59/100 and a GF Value™ of $3.23. The stock has 11 warning signs investors should review. Among 703 Medical Devices & Instruments companies, MicroPort CardioFlow Medtech ranks worse than 82.65% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for MicroPort CardioFlow Medtech's Debt-to-Equity or its related term are showing as below:
MROPF'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.05 Med: 0.04 Max: 0.91
Current: 0.91
During the past 8 years, the highest Debt-to-Equity Ratio of MicroPort CardioFlow Medtech was 0.91. The lowest was -0.05. And the median was 0.04.
MROPF's Debt-to-Equity is ranked worse than 82.65% of 703
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs MROPF: 0.91
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
MicroPort CardioFlow Medtech Debt-to-Equity Related Terms
MicroPort CardioFlow Medtech Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, MicroPort CardioFlow Medtech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MicroPort CardioFlow Medtech Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MicroPort CardioFlow Medtech's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where MicroPort CardioFlow Medtech's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MicroPort CardioFlow Medtech (MROPF) has a Debt-to-Equity of 0.91 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on MicroPort CardioFlow Medtech and its competitors. This is 2175% above median its historical median of 0.04. According to the industry distribution chart, MicroPort CardioFlow Medtech ranks #581 out of 703 companies in the Medical Devices & Instruments industry, placing it in the top 82.6%.
Is MicroPort CardioFlow Medtech's Debt-to-Equity too high?
MicroPort CardioFlow Medtech's current Debt-to-Equity of 0.91 is 2175% above median its 10-year median of 0.04. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. MicroPort CardioFlow Medtech's value of 0.91 is 295.7% above this industry median. Based on the distribution chart, MicroPort CardioFlow Medtech ranks #581 out of 703 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, MicroPort CardioFlow Medtech has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does MicroPort CardioFlow Medtech's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MicroPort CardioFlow Medtech ranks #581 out of 703 companies for Debt-to-Equity. This places MicroPort CardioFlow Medtech in the lower half of its industry. The industry median Debt-to-Equity is 0.23. MicroPort CardioFlow Medtech's value of 0.91 is 295.7% above this benchmark. While the company's 10-year median is 0.04 vs. the industry median of 0.23, MicroPort CardioFlow Medtech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MicroPort CardioFlow Medtech's current Debt-to-Equity of 0.91 is 295.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on MicroPort CardioFlow Medtech and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MicroPort CardioFlow Medtech's current Debt-to-Equity is 0.91, which is 2175% above median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MicroPort CardioFlow Medtech stock overvalued right now?
MicroPort CardioFlow Medtech (MROPF) has a current Debt-to-Equity of 0.91. The stock's GF Value™ is $3.23, compared to a current price of $0.65 — trading 80% below its estimated fair value. The current Debt-to-Equity is 0.91, which is 2175% above median its 10-year median of 0.04 and 295.7% above the Medical Devices & Instruments industry median of 0.23. MicroPort CardioFlow Medtech's overall GF Score™ is 59/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For MicroPort CardioFlow Medtech (MROPF), the current Debt-to-Equity is 0.91 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MicroPort CardioFlow Medtech (MROPF) Overvalued in 2026?
Based on GuruFocus' analysis, MicroPort CardioFlow Medtech stock appears to be undervalued.
The current stock price of $0.65 is trading 80% below its estimated GF Value™ of $3.23.
Key valuation signals for MROPF:
Debt-to-Equity: 0.91 (2175% above median its 10-year median of 0.04)
GF Value™: $3.23 vs. price of $0.65 (80% below fair value)
Industry Position: 295.7% above the Medical Devices & Instruments median (#581 of 703)
No single metric tells the full story. See the MROPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MicroPort CardioFlow Medtech Corp is a medical device company in China focusing on the research, development, and commercialization of transcatheter and surgical solutions for valvular heart diseases. The company's product portfolio consists of VitaFlow, VitaFlow Liberty, Angelguide and AnchorMan. The Group derives revenue from the sales of medical devices through appointed distributors. It derives maximum revenue from PRC.
59GF Score
Get the complete analysis for MROPF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MROPF has been successfully added to your 
